Although 18F-labeled NaF was the first widely used agent for skeletal scintigraphy, it quickly fell into disuse after the introduction of 99mTc-labeled bone-imaging agents. Recent comparative studies have demonstrated that 18F-fluoride PET is more accurate than 99mTc-diphosphonate SPECT for identifying both malignant and benign lesions of the skeleton. Combining 18Ffluoride PET with other imaging, such as CT, can improve the specificity and overall accuracy of skeletal 18F-fluoride PET and probably will become the routine clinical practice for 18Ffluoride PET. Although 18F-labeled NaF and 99mTc-diphosphonate have a similar patient dosimetry, 18F-fluoride PET offers shorter study times (typically less than 1 h), resulting in a more efficient workflow, improved patient convenience, and faster turnarounds of reports to the referring physicians. With the widespread availability of PET scanners and the improved logistics for the delivery of 18F radiopharmaceuticals, prior limitations to the routine use of 18F-fluoride bone imaging have largely been overcome. The favourable imaging performance and the clinical utility of 18Ffluoride PET, compared with 99mTc-diphosphonate scintigraphy, support the reconsideration of 18F-fluoride as a routine bone imaging agent. Key Words: 18F-labeled sodium fluoride, skeletal PET
at 1 and 6 mo after the beginning of treatment. Dynamic acquisition and arterial blood sampling were used to calculate the influx constant Ki (by both the Patlak [Ki-PAT] method and the nonlinear regression [Ki-NLR] method). Kinetic modelling was compared with maximal standardized uptake values (SUVmaJ and biochemical markers of bone remodelling. Results: Baseline uptake of 18F-fluoride by pagetic bones was significantly higher than in normal bones (P < 0.05). One month after the start of treatment, SUVmax ,Ki-PAT, Ki-NLR, and KI (the unidirectional clearance of fluoride from plasma to the whole of the bone tissue) decreased significantly by 27.8%,27.9%,27.5%, and 23.6%, respectively. Biochemical markers were already normalized in 6 of9 patients with monostotic disease, although all had high 18F-fluoride uptake values. Six months after the start of treatment, 18F-fluoride uptake further diminished by 22.3%-25.6%. Biochemical markers were normal in all but 2 patients, although 10 of 14 patients still showed high 18F_ fluoride uptake. One patient did not respond to treatment and maintained high uptake of 18F-fluoride throughout the study. SUV max correlated with both Ki-PA T and Ki-NLR at baseline, 1 mo, and 6 mo (P < 0.05). Moreover, the change of SUV max between baseline and 1 mo, as well as between baseline and 6 mo, also correlated with the change of Ki-PAT and Ki-NLR (P < 0.05). Conclusion: Our results show that J8F-fluoride PET can be used to no invasively and accurately monitor the efficacy of treatment with bisphosphonates in Paget's disease of bones. SUV max correlates with Ki-PA T and Ki-NLR and, interestingly, varies in the same manner as kinetic indices. Therefore, the use of SUV max could avoid the need for dynamic acquisition and arterial blood sampling and would facilitate the use of whole-body PET in a clinical setting.
The up-regulation of rates of choline uptake and phosphorylation in certain malignancies has motivated the development of positron-labeled choline analogues for noninvasive detection of cancer using positron emission tomography (PET). The choline analogue, no-carrier-added [18F]fluoromethyl-dimethyl-2-hydroxyethyl-ammonium (FCH), was synthesized through the intermediate [18F]fluorobromomethane. FCH was evaluated in relationship to 2-[18F]fluoro-2-deoxyglucose (FDG) as an oncological probe in cultured PC-3 human prostate cancer cells, a murine PC-3 human prostate cancer xenograft model, and in PET imaging studies of patients with prostate cancer. FCH was synthesized in 20-40% radiochemical yield and >98% radiochemical purity. Accumulation of FCH and FDG were comparable in cultured prostate cancer cells, whereas only FCH was inhibited (90%) by hemicholinium-3, a specific inhibitor of choline transport and phosphorylation. FCH showed similar biodistribution to [14C]choline in the tumor-bearing mouse, with prominent renal and hepatic uptake. Tumor uptake of FCH was similar to choline and FDG in the mouse model, although tumor:blood ratios were moderately higher for FCH. Initial PET imaging studies in prostate cancer patients showed high uptake of FCH in advanced prostate carcinoma and detection of osseous and soft tissue metastases. FCH uptake by tumors was markedly reduced in patients rescanned during androgen deprivation therapy. It is concluded that FCH closely mimics choline uptake by normal tissues and prostate cancer neoplasms. FCH is potentially useful as a PET tracer for detection and localization of prostate cancer and monitoring effects of therapy. This study compared 18F-fluorocholine uptake in malignant and benign areas of the prostate at 2 time points to determine the suitability of delayed or dual-phase 18F-fluorocholine PET for localizing malignancy in the prostate gland. Methods: Twenty-six men (15 newly diagnosed with prostate cancer, 2 with recurrent prostate cancer, 6 with no evidence of prostate cancer recurrence after treatment, and 3 with no history of prostate cancer) underwent dual-phase PET consisting of initial whole-body PET starting 7 min after injection of 3.3-4 MBq/kg of 18F-fluorocholine followed by 1-h delayed PET of the pelvis. Tracer uptake in the prostate on the initial and delayed images was measured on a sextant basis. Prostate biopsy or whole-prostate histologic examination after radical prostatectomy was used to classify a prostate sextant as a dominant malignant region or probable benign region. For each sextant, a retention index based on the measured maximum standardized uptake value (SUVmax) was calculated on the initial and delayed images. In 15 prostates with both benign and malignant sextants on histologic examination, a malignant-to-benign ratio of SUVmax was also calculated for each time point. Results: A dominant malignant region was found in 17 subjects, and a probable benign region was found in 24 subjects. The mean SUVmax for dominant malignant regions increased significantly between initial and delayed scans, from 7.6 to 8.6 (mean retention index, 114%; 95% confidence interval, 6%-22%; P 5 0.002). The mean SUVmax for probable benign regions decreased significantly between initial and delayed scans, from 4.8 to 3.9 (mean retention index, 217%; 95% confidence interval, 210% to 223%, P , 0.001). The mean malignant-to-benign ratio increased significantly, from 1.4 on the initial scan to 1.8 on the delayed scan (P 5 0.003). The areas under the receiver operating characteristic curves for distinguishing dominant malignant regions from probable benign regions based on initial SUVmax, delayed SUVmax, and retention index were 0.81, 0.92, and 0.93, respectively. Conclusion: On dual-phase PET of the prostate, areas of malignancy consistently demonstrated stable or increasing 18F-fluorocholine uptake, whereas most areas containing benign tissue demonstrated decreasing uptake. Delayed or dual-phase imaging after injection of 18F-fluorocholine may improve the performance of 18F-fluorocholine PET for localizing malignant areas of the prostate.
Localization of Primary
Role of whole-body 18F-cholinePET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer Purpose: The aim of this study was to evaluate the role of whole body 18F-choline(FCH) positron emission tomography-computed tomography (PET-CT) in detecting and localising disease recurrence in patients presenting biochemical relapse after radical treatment for prostate cancer. Materials and methods: Fifty-six consecutive patients with increased serum prostate-specific antigen (PSA) levels after radical prostatectomy were included in the study. None of them was recei ving hormone treatment at the time f the examination or had been treated during the previous 6 months. All patients underwent whole-body 18F-choline PET imaging, and the pathological findings were compared with those of further imaging exams, biopsy and follow-up. On the basis of the PSA levels, we divided our patient population into three subgroups: PSA≤1, l <PSA≤5, and PSA>5 ng/ml. Results. Overall, the PET scan detected disease relapse in 42.9% of cases (24/56). PET sensitivity was closely related to serum PSA levels, showing values of 20%, 44% and 81.8% in the PSA≤I, I<PSA≤5 and PSA>5ng/ml subgroups, respectively. Conclusions: In patients with biochemical relapse after radical treatment for prostate cancer, 18F-cholinePET-CT represents a single step, whole-body, non-invasive study that allows disease detection and localisation. The disease detection rate is related to serum PSA levels.
Fluoromethylcholine (18F) PET/CT for staging hepatocellular carcinoma: prospective comparison with FDG (18F) PET/CT
S. Balogova PET/CT for staging HCC, according to its diferentiation. Methods: 34 patients with newly diagnosed (n=27) or recurrent (n=7) HCC were prospectively enrolled. HCC was assessed by histology in 29 cases (11 well-differentiated HCC) and by European Association for the study of the liver ("Barcelona") criteria in 5 cases. All patients underwent whole-body PET/CT 10 min a=er injection of 4 MBq/kg FCH. Within 1 week, all patients underwent whole-body FDG PET/CT 1 h a=er injection of 5 MBq/kg FDG. On basis of histology, 70 hepatic lesions and 3 extra-hepatic lesions were evaluable. Results:The per-patient analysis showed a detection rate of 27/34=79% using FCH PET/CT and 23/34=68% (NS) using FDG PET/CT for both newly diagnosed and recurrent HCC. On a per patient basis, FCH or FDG were positive in 32/34 = 94% HCC patients. !e 2 patients who were "missed" by both FCH and FDG were alive more than 24 months after inclusion. On a per site basis, of the 64/70 = 91% liver lesion sites were detected by FCH or FDG, only 6 lesions being missed by both radiopharmaceuticals. In patients with well-differentiated HCC (11/34) a significant superiority of detection was observed with FCH 11/11=100% vs. 5/11=45% with FDG, p<0,003, on a per patient basis and 30/32=94% vs. 19/32=59% on per liver lesion basis. Furthermore 5 liver HCC lesions appeared photopenic on FCH PET/CT. !e 3 distant metastatic sites were visible with both FCH and FDG. Concordantly with what was observed for liver lesions, the metastatic site corresponding to a primary well-differentiated HCC took up FCH more avidly than FDG (SUV=10.6 vs. 2.7 respectively), and the reverse was true in 2 cases of lung or mediastinum metastases of nonwell-differentiated HCC. Aim: We have shown in a proof-of-concept study that FCH was taken-up by HCC more frequently than FDG. the aim of this prospective study was to compare the diagnostic performance of FCH and FDG to detect HCC in 58 patients with chronic liver disease and nodule(s). Methods: 59 patients (40M, 19F, age 33-77) underwent whole-body FCH PET/CT 10 min after injection of 4 MBq/kg and whole-body FDG PET/CT 1 h after injection of 5 MBq/kg FDG. A=er the end of inclusions, both PET/CT examinations were blind read in a random order for each tracer by 2 independent observers using the standard 5 level scale (0: no lesion or most probably benign lesion, 4: most probably malignant lesion) and the consensus of blind readings was reached. Diagnostic performance of each tracer was calculated on per patient and per lesion-site bases. Results: On basis of histology and/or follow-up >6 months, the 59 patients had 34 HCC, 4 cholangiocarcinoma, 2 liver metastasis of colon cancer, 2 pulmonary cancers without primary or secondary liver cancer, 14 liver adenoma and/or focal nodular hyperplasia, and 3 another benign hepatic lesion. Per patient performance of FCH & FDG for detecting presence of HCC, any positive result in another cancer being considered FP.
Results-[18F]FCH and [14C]choline were similarly metabolized in 9L cells in both normoxic
and hypoxic conditions over a 2 hr incubation period. In normoxia, radioactivity was predominantly in phosphorylated form for both tracers after 5 min incubation. In hypoxia, the tracers remained mainly in nonmetabolized form at early timepoints (< 20 min). Slow 
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Object. Neuroimaging-guided stereotactic biopsy procedures are commonly used for diagnosis of gliomas. A number of the imaging modalities currently in use are not reliable enough in depicting these tumors. The authors developed 18Fcholine and 11C-choline as tumor imaging agents for positron mission tomography (PET) scanning, and used them to visualize gliomas prior to stereotactic biopsy procedures. Methods. The PET studies were performed in 12 patients who were thought to be affected by gliomas observed on computerized tomography and magnetic resonance images. The 18F-and 11C-choline were injected separately, and the PET scanning was started 5 and 20 minutes postinjection. The PET scans gave quantitative information about the distribution of 18F-and 11C-choline in the brain. The tumor uptake was constant between 5 and 20 minutes with both agents. Stereotactic biopsy sampling was performed to obtain tissues from the most radioactive areas on the PET scan; histological diagnoses were made using these tissues. The results were as follows: oligodendroglioma was found in two patients, astrocytoma in one, anaplastic astrocytoma in two, and glioblastoma in seven. Conclusions. The uptake of contrast agents was always low in low-grade gliomas, and the uptake in high-grade glioma was always high. The tumor/normal (T/N) ratio of 18F-choline was 10.5:12 in anaplastic astrocytoma and 13.2:21 in glioblastoma. The 18F-choline yielded slightly superior results compared with 11C-choline with regard to the T/N ratio. In one case of oligodendroglioma the tumor showed no uptake of 18F-and 11C-choline. With this exception, the PET scans of gliomas in which 18F-and 11C-choline contrast agents were added would guide the approach to the most malignant areas for stereotactic biopsy sampling. [18F]MISO is the prototype hypoxia imaging agent. Uptake is homogeneous in most normal tissues, reflecting its high partition coefficient (near unity), and delivery to tumours is not limited by perfusion [14] . The initial distribution of [18F]MISO is flow dependent, as with any freely diffusible tracer, but local oxygen tension is the major determinant of its retention above normal background in tissues after 2 h. [18F]MISO accumulates in tissues by binding to intracellular macromolecules when pO2 < 10 mmHg. Retention within tissues is dependent on nitroreductase activity (i.e. on reduction status of a NO2 group on the imidazole ring) and accumulation in hypoxic tissues over a range of blood flows has been noted, including within the intestinal lumen where it is retained in anaerobes. Hypoxia can be imaged with [18F]MISO PET in a procedure that is well tolerated by the patients. Imaging requires 20-30 min and starts anywhere from 75 to 150 min after injection, making it similar to the bone scan with which most cancer patients are familiar. Useful and well-validated images can be achieved with a modest dose of radiation, typically 250 MBq. No arterial sampling or metabolite analysis is required and synthesis is achieved through relatively simple modifications of nucleophilic displacement/deprotection synthesis boxes such as are used for fluorodeoxyglucose ([18F]FDG). In the United States, F-MISO has Investigational New Drug (IND) authorization from the Food and Drug Administration (FDA) as an investigational product for use in humans. Unlike Eppendorf pO2 histography, [18F]MISO is only sensitive to the presence of hypoxia in viable cells; [18F]MISO is not retained in necrosis because the electron transport chain that reduces the nitroimidazole to a bioreductive alkylating agent is no longer active. Limitations of [18F]MISO PET include the modest signal-to-noise ratio of raw [18F]MISO PET images but if a venous blood sample is acquired during the mid-course of the imaging procedure and used to calculate a tumour/blood (T/B) ratio image, then normoxic uptake (T/B < 1) can be electronically subtracted to increase image contrast. Several studies in a range of hypoxic tumours, stroke and hypoxic myocardium [15] have shown that a T/B of >1.2 reliably identifies the presence of hypoxia. The presence of high normal liver uptake impairs complete assessment of liver lesions and urinary excretion interferes with imaging near the bladder.
[18F]MISO PET is able to monitor the changing hypoxia status of lung tumours during radiotherapy [16] . Studies in sarcoma [17] and head and neck cancer [18] [19] [20] In a univariate analysis,T/Bmax (P = 0.002),HV(P = 0.04 ), and the presence of nodes (P = 0.01) were strong independent predictors. In a multivariate analysis, including FDG SUVmax, no variable was predictive at P < 0.05.When FDG SUVmax was removed from the model (resulting in n = 73 with 28 events), nodal status andT/Bmax (or HV) were both highly predictive (P = 0.02, 0.006 for node andT/Bmax, respectively; P = 0.02 and 0.001for node and HV, respectively).
Conclusions: Pretherapy FMISO uptake shows a strong trend to be an independent prognostic measure in head and neck cancer.
Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, Machulla HJ, Bares R. In radiotherapy of head and neck cancer (HNC) and non-small cell lung cancer (NSCLC), hypoxia is known to be an important prognostic factor for long-term survival and local tumor control. The PET tracer (18)F-fluoromisonidazole (FMISO) allows noninvasive assessment of tumor hypoxia. This study analyzed whether FMISO PET could predict tumor recurrence after radiotherapy. METHODS: Forty patients with advanced HNC (n = 26) or NSCLC (n = 14) were studied before curative radiotherapy. Dynamic (0-15 min) and static PET scans were acquired up to 4 h after injection of 400 MBq of FMISO. Standardized uptake values (SUVs) and ratios to reference tissues (mediastinum or muscle) were calculated. In addition, time-activity curves up to 14 min after injection were classified visually. PET data were correlated with clinical follow-up data (presence or absence of local recurrence within 1 y), which were available for 21 patients. RESULTS: For HNC, patients with local recurrence could be separated from disease-free patients by SUV 4 h after injection (all recurrences had an SUV > 2). For NSCLC, no such correlation was observed. The tumor-to-muscle ratios (T/Mu) and tumor-to-mediastinum ratios (T/Me) at 4 h after injection correlated with the risk of relapse in both tumor entities: All patients with a T/Me greater than 2.0 (NSCLC, n = 5) or with a T/Mu greater than 1.6 (HNC, n = 5) presented with tumor recurrence, whereas only 3 of the remaining 11 patients experienced recurrence (27%). Qualitative analysis of time-activity curves for 37 patients revealed 3 curve types (rapid washout, n = 9; intermediate [delayed washout], n = 12; and accumulation, n = 16). Eighteen patients categorized by curve type could be followed up: In 5 of 6 patients with an accumulation curve, disease recurred locally within 1 y, compared with 5 of 8 patients with a delayed-washout curve and 0 of 4 with a rapid-washout curve. CONCLUSION: Our results indicate that outcome after radiotherapy can be predicted on the basis of kinetic behavior of FMISO in tumor tissue. An accumulation-type curve, high SUV, and high T/Mu and T/Me at 4 h after injection are highly suggestive of an incomplete response to treatment and might be used to select patients for intensified therapy protocols.
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